Tislelizumab in Combination With Eribulin for Patients With Metastatic Previously heaviLy-treAted TriplE-negative Breast Cancer：A Prospective Multiple-center Phase II Study
Clinical trial NCT04913571 · UNKNOWN
Trial details
- NCT number
- NCT04913571
- Sponsor
- Fudan University
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-05-27
- Primary completion
- 2022-06-01
- Enrollment
- 265
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.